204 Users Online
Radiotherapy-Induced Nausea and Vomiting Treatment Market Segmented By Serotonin (5-HT3) receptor antagonist, Neurokinin-1 (NK1) receptor antagonist, Corticosteroids, Dopamine antagonists Drug
According to the latest research by Persistence Market Research, Radiotherapy-induced nausea and vomiting Treatment market is set to witness a 6.1% growth during the year 2021-2031. The market is expected to witness growth owing to increase in number of patients going through radiotherapy or chemotherapy and the growing compliance to CNIV drugs because of rise in utilization of novel drug delivery methods like transdermal patches & combination therapies.
Moreover, the market is furthermore influenced by technology advancements to discover novel high potential drugs, hence creating lucrative opportunities in the market.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The demand for the global market for radiotherapy-induced nausea and vomiting is anticipated to grow on account of the increasing occurrence of different types of cancers worldwide.
Moreover, strong research and development in oncology treatment, the increase in the occurrence of cancer cases, growing preference toward chemotherapy for the treatment of cancer and the usage of chemotherapy in together with other cancer treatments are expected to drive the growth of radiotherapy-induced nausea and vomiting.
In addition, increasing occurrence of cancer and developments in research and development of medicines will help in boosting the development of the market.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionCancer is one of the leading cause of death across the world. As per the National Institutes of Health (NIH), in 2018, around 1,735,350 new cases of cancer were detected in the United States and 609,640 people died from the disease.
Cancer can be treated by chemotherapy, surgery, hormone therapy, radiation therapy, targeted therapy, stem cell transplantation and precision medicine. The most common therapy for cancer is chemotherapy; it utilizes drugs to eradicate cancer cells which lead to pain and other problems. Chemotherapy can be used together with other cancer treatments.
Chemotherapy, kills the cancer cells as well as attacks healthy cells which results into side effects such as hair loss, fatigue, nausea, and vomiting. Radiotherapy-Induced Nausea and Vomiting is one of the most severe side effects which is taken into consideration. Radiotherapy-induced nausea and vomiting are categorized as acute, which occurs in 24 hours of the treatment. This is leading to the market growth.
The US and Canada Radiotherapy-induced nausea and vomiting Treatment market is expected to observe a robust growth in the market owing to the increasing on account of the presence of various cancer-relief organizations and campaigns in the US and Canada.
Also, rising number of cancer cases is expected to boost the market in US. As per the American Cancer Society’s annual report, around 1.6 million population was affected by cancer in US in 2017 and hence it is expected to occupy the highest market share in the market. In addition, advantageous government initiatives and rise in the number of research partnerships are few of the factors anticipated to increase market growth.
Sales Team
Client Partner
Europe is expected to be second most lucrative region for market owing to several factors. The increasing patient pool leads to a high rate of CINV drugs adoption because of rising number of patients with chemotherapeutic associated side effects. Moreover, the increase in cancer patients, focus on merger and acquisition by various key manufacturers and funding by the governmental bodies is expected to lead to market growth.
Some of the leading manufacturers and suppliers of Radiotherapy-induced nausea and vomiting Treatment include
The market is moderately competitive with presence of various major players. Technology partnerships and collaborations by the major players in the market with a view to bridge the demand-supply gap is expected to play a key role in development of the market.
Also, major players are funding largely in the in the research and development to produce advanced products. Worldwide, they are involved in long term contracts with medical care organizations, and are involving into partnerships and strategic alliances with other players in various nations to extend their business.
By Drug Type
By Route of Administration
By Distribution Channel
By Region
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
